Lonza Invests in Viral Gene and Cell Therapies Facility
PTSM: Pharmaceutical Technology Sourcing and Management
Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies
Lonza announced on June 16 the planned construction of a 100,000-sq-ft facility for viral and immunotherapy development and manufacturing in the Houston, TX area. The new facility will more than double Lonza’s capacity for the production of viral gene and virally modified therapeutics and will include a segregated fill/finish suite, the company reports.
The multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.
Source: Lonza
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
